Compare ALXO & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALXO | EARN |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.9M | 169.8M |
| IPO Year | 2020 | 2012 |
| Metric | ALXO | EARN |
|---|---|---|
| Price | $1.79 | $4.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $3.50 | ★ $5.38 |
| AVG Volume (30 Days) | ★ 1.4M | 381.3K |
| Earning Date | 05-08-2026 | 06-16-2026 |
| Dividend Yield | N/A | ★ 20.51% |
| EPS Growth | ★ 26.36 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $7.69 |
| Revenue Next Year | N/A | $19.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $4.27 |
| 52 Week High | $2.66 | $6.08 |
| Indicator | ALXO | EARN |
|---|---|---|
| Relative Strength Index (RSI) | 54.99 | 42.33 |
| Support Level | $1.54 | $4.27 |
| Resistance Level | $2.27 | $4.78 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 97.62 | 32.61 |
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.